Asset Details
Do you wish to reserve the book?
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
Do you wish to request the book?
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
2015
Overview
Patients with multivessel coronary artery disease were randomly assigned to PCI with everolimus-eluting stents or CABG. At 2 years, the composite of death, myocardial infarction, or target-vessel revascularization occurred more frequently in the PCI group.
Randomized trials and observational studies have shown that the rates of most adverse clinical outcomes among patients with multivessel coronary artery disease are lower after coronary-artery bypass grafting (CABG) than after percutaneous coronary intervention (PCI).
1
–
7
Current clinical guidelines thus recommend CABG as the preferred revascularization strategy, particularly in patients with complex coronary lesions and without excessive operative risk.
8
,
9
However, previous trials may have been limited by their use of first-generation drug-eluting stents. Although these stents reduced the rate of restenosis, their use was associated with a relatively high rate of stent-related thrombotic events.
10
Results from the Synergy between . . .
Publisher
Massachusetts Medical Society
Subject
/ Coronary Artery Disease - surgery
/ Coronary Artery Disease - therapy
/ Coronary Restenosis - epidemiology
/ Diabetes Complications - therapy
/ Female
/ Humans
/ Implants
/ Male
/ Myocardial Infarction - epidemiology
/ Myocardial Infarction - prevention & control
/ Percutaneous Coronary Intervention
/ Sirolimus - administration & dosage
/ Sirolimus - analogs & derivatives
/ Stents
